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Chapter 1 
 
INTRODUCTION 
Hepatitis C virus (HCV) infection represents a major public health problem and is 
considered as one of the most lethal infectious diseases next to influenza, 
respiratory syncytial virus, rotavirus, hepatitis B (HBV) and human 
immunodeficiency virus (HIV) [1,2]. The World Health Organization (WHO) 
estimates that at least 130-150 million people, approximately 3% of the world’s 
population, are chronically infected causing about 700,000 deaths every year [3]. 
Chronic HCV infection may lead to hepatic fibrosis and eventually cirrhosis, at 
which stage patients have a substantial risk of liver failure, hepatocellular 
carcinoma (HCC) and liver-related death; moreover, HCV infection is associated 
with several extrahepatic manifestations which increase the non-liver-related 
mortality rate and have a strong impact on health-related quality of life and on 
direct and indirect health care costs [4,5].  
Over the last few years this viral disease even gained prime focus in medicine in 
general; this momentum of chronic HCV infection results from the success story of 
antiviral treatment development. Interferon-based antiviral therapy, aimed at 
immunomodulation to inhibit HCV replication, has been a treatment option for 
over two decades; in the recent five years, new interferon-free antiviral drugs, called 
direct-acting antivirals (DAAs), have been developed and revolutionized the 
treatment of HCV because they are much more effective, safer and better-tolerated 
than the older therapies [6]. 
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1.1 An overview of HCV: origin, epidemiology and diversity 
HCV is a Hepacivirus that belongs to the Flaviviridae family, first discovered in 1989 
by Choo and coworkers from the serum of a patient with non-A, non-B hepatitis [7]. 
Although its origin remains unclear, this virus might be originated from zoonotic 
sources such as non-human primates (e.g. monkeys, apes) and mammals (e.g. dogs, 
horses) [8].  
A single HCV particle display a diameter of approximately 68 nm and it consists of 
a core of genetic material, surrounded by an icosahedral protective shell of proteins 
further encased in a lipid envelope of cellular origin [9]. The viral genome is made 
up of a linear positive-sense single-stranded RNA, whose total length is about 9.6 
kb, with one open reading frame (ORF) and 5’ and 3’ untranslated regions (UTRs) 
at both edges (Fig. 1) [10].  
 
 
 
Figure 1. HCV genome. Structural and non-structural proteins encoded by HCV RNA 
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The open reading frame is translated to produce a single protein product 
(polyprotein) which is then cleaved, by viral and cellular proteases, into 10 
structural and non-structural (NS) proteins: the first group, including core protein 
(C) and the envelope proteins E1 and E2, constitutes the skeletal structure of the 
virion, while P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B, that are part of the 
second group, act as enzyme or regulatory factors that are essential for viral 
replication. Core protein modulates gene transcription, cell death, cell proliferation 
and interference metabolism leading to oxidative stress, liver steatosis and finally 
hepatocellular carcinoma (HCC); HCV envelope proteins E1 and E2 are generally 
glycosylated and have played a major role in cell entry; protein P7 is responsible for 
ion channel and virus assembly [11]. 
Among non-structural proteins, NS3 functions as a serine protease and forms a 
heterodimeric complex with NS4A that acts as a cofactor of the proteinase; the NS2 
cysteine auto-protease and the NS3/4A serine protease are responsible for the 
cleavage of downstream, non-structural proteins, including NS5A. NS5A is a 
hydrophilic phosphoprotein which plays an important role in viral replication, 
modulation of cell signaling pathways and the interferon (IFN) response. The NS5B 
protein is the viral RNA dependent-RNA polymerase, which catalyzes the 
polymerization of ribonucleoside triphosphates (rNTP) during RNA replication. 
Given the critical role of NS3/NS4A, NS5A and NS5B in the viral life cycle, they are 
currently focused on as major targets in development of DAAs. 
RNA replication takes place in distinct compartments of the cell cytoplasm and 
requires both viral (NS3-NS5) and host proteins. During replication, HCV genomic 
RNA is transcribed into a complementary RNA strand, which subsequently 
constitutes a template for the synthesis of new viral genomes [12]. Owing to the 
highly error prone of the RNA polymerase, and to the resulting low fidelity of the 
genomic RNA replication, a naturally high rate of genetic mutation generates 
genetic diversity of HCV. Based on the sequence variation of different HCV strains, 
it is possible to identify 7 genotypes (genotype 1-7) with several subtypes within 
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each of them, whose global prevalence is unevenly distributed: in particular, 
genotype 1 (46,2%) and 3 (30,1%) dominate the global infections; genotypes 2, 4 and 
6 characterize about 22,8% of HCV infections; genotype 5 accounts for the 
remaining less than 1% [13] and finally genotype 7 has been identified so far in very 
few patients originating from Central Africa [14]. Interestingly, the nucleotide 
diversity of HCV genomes is approximately 32,4% between virus genotypes and 
14,6% within each of them [15]. Genotype is clinically important in determining 
potential response to therapies; genotypes 1 and 4, for example, are less responsive 
to IFN-a-based treatment than are the others [16], and this leads to difficulties in 
clearing HCV infection of these two genotypes. On the other hand, the latest 
developed Direct-Acting Antivirals (DAAs) have the potential to eradicate all 
genotypes of HCV, hence extending the patient population who may benefit. 
 
1.2 HCV-related lymphoproliferative disorders 
Patients with chronic HCV infection are known to be at risk of developing liver 
complications, such as cirrhosis and hepatocellular carcinoma (HCC), but the 
morbidity and the mortality are underestimated because they don’t take into 
account the extrahepatic manifestations of HCV infection. Indeed, although 
hepatocytes are the primary target, early after its discovery it was shown that this 
virus is not only hepatotropic but also lymphotropic [17]: Muller et al. first reported 
in 1993 that HCV RNA could be found in B cells [18] and they predicted that 
peripheral blood mononuclear cells (PBMCs), particularly B cells, could be sites for 
HCV replication and may serve as reservoirs of HCV infection; many subsequent 
studies have confirmed that HCV may also infect PBMCs [19-21] as indicated by the 
presence of HCV RNA, as well as structural and non-structural viral proteins, in 
PBMCs of chronically HCV-infected patients or in perihepatic lymph nodes [21-23]; 
other studies have reported the ability of serum-derived HCV particles to infect 
PBMCs [24,25] or particular human T-cell leukemia virus type 1- infected cell lines 
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[26]; finally, a study reported the establishment of a B-cell line deriving from a HCV-
infected patient non-Hodgkin’s B-cell lymphoma (B-NHL) [27].  
As a consequence of the lymphatic infection, several lymphoproliferative disorders 
(LPDs) have been associated with this virus [28], including Type II Mixed 
Cryoglobulinemia (MC), B-NHL [29,30] and monoclonal gammopathies [31].  
A number of evidence suggests that the way through which HCV causes LPDs is 
represented by the protracted antigenic stimulation [32,33]. Interestingly, this 
hypothesis is strengthened by the preferential usage by the monoclonal B cells 
expanded in HCV-related LPDs of a restricted set of cross-idiotypes (XId), 
commonly encoded by IGHV1-69, IGKV3-A27 and IGKV3-20 heavy chain variable 
genes [34-37].  
It has been postulated that HCV proteins may facilitate B cell activation through 
different mechanisms: one of these is the binding between HCV envelope protein 
E2 and the tetraspanin CD81 expressed on B cell surface, that leads to the formation 
of a co-stimulatory complex with CD19 and CD21, induces a decrease in B cell 
activation threshold and subsequently triggers the JNK pathway leading to B cell 
proliferation [38]; another mechanism is the interaction of the HCV nonstructural 
protein NS3/4A with the DNA damage sensor CHK2, leading to a cascade of events 
that upregulate BCR signaling [39]. Conversely, HCV infection of memory B cells 
through the binding of E2 and 5’-UTR to the  
B7.2 (CD86) co-receptor inhibits differentiation into plasmablasts and 
immunoglobulins (Igs) production [40].  
Interesting data are available about the role played by chromosomal aberrations in 
HCV-related LPDs. The most investigated genetic aberration was the (14;18) 
translocation, that was found to be significantly associated with type II or 
monoclonal MC. The presence of this translocation in MC was correlated with the 
overexpression of the anti-apoptotic bcl-2 gene in B cells, resulting in an imbalance 
of the Bcl-2/Bax ratio and abnormal B cell survival [41,42] (Fig. 2). It has been 
reported an increased rate of aneuploidy in chronically infected HCV subjects 
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versus healthy controls, with values similar to an NHL group. This observation 
suggests that HCV patients could be more prone to develop a lymphatic 
malignancy also because of bearing such alterations of the ploidy grade [43]. Finally, 
a growing body of evidence support the key role of cytokines and chemokines [44], 
as well as of microRNA (miRNA) [45], in the pathogenesis of chronic HCV infection 
and related extrahepatic disorders (Fig. 2). 
 
 
 
 
Figure 2. HCV-related pathogenesis is a multifactorial and multistep process.  
Current data suggest that the starting points of this process are represented by the cooperation 
between a sustained and persistent stimulation, by direct or indirect action of viral particles or 
proteins, and anti-apoptotic mechanisms acting on B cell compartment. A predisposing genetic 
background would be responsible for the final evolution to a particular LPD (namely, mixed 
cryoglobulinemia). The progressive addition of genetic aberrations would lead to a frank neoplastic 
transformation, gradually making the process less dependent on the etiologic agent [41-45]. 
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1.3 Cryoglobulinemia: physical properties of cryoglobulins, diagnosis and 
laboratory evaluation 
The term “cryoglobulinemia” refers to a clinical condition characterized by the 
presence of immunoglobulins in serum that precipitate, in vitro, at temperature 
below 37°C and redissolve after rewarming; these cold-precipitable 
immunoglobulins were first identified by Wintrobe and Buell in 1933 and 
subsequently named “cryoglobulins” by Lerner and coworkers in 1947 [46]. 
Interestingly, cryoglobulins are not necessarily a sign of disease since healthy 
people may have low concentrations of them and polyclonal cryoglobulins may be 
transiently detected during infection [47].  
In 1974, Brouet et al [48] proposed a classification of cryoglobulinemia that is still 
widely used due to its good correlation with clinical features and associated 
diseases:  
 
- monoclonal cryoglobulinemia (type I)  
- mixed cryoglobulinemia (type II and type III)  
 
In Type I cryoglobulinemia, cryoglobulins, which account for 10-15% of the total, 
are composed of a single monoclonal cryoprecipitable immunoglobulin (mainly 
IgG or IgM and rarely IgA or free immunoglobulin light chains [49]) produced by 
the monoclonal expansion  
of a B cell clone that may be indolent in about 40% of patients (monoclonal 
gammopathy of unknown significance [MGUS]) or overtly malignant in the 
remaining 60% (Waldenström macroglobulinemia [WM], multiple myeloma [MM] 
or chronic lymphocytic leukemia [CLL]) [50]. In type II cryoglobulinemia, 
cryoglobulins, which account for almost 50-60% of cases, are characterized by a 
polyclonal component, mainly IgG, mounting k or 𝜆 chains, and a monoclonal IgM 
(rarely represented by IgA or IgG) endowed with rheumatoid factor (RF) activity. 
Most IgM react with both intact IgG and the F(ab)2 fragment and also with the Fc 
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fragment of autologous IgGs, and these two types of molecular interaction confer 
greater stability to cryoprecipitating IgM-IgG immune-complexes. This type of 
cryoglobulinemia is usually associated with HCV infection in up to 90% of patients 
[51]; different causes include other infections (mainly HIV and HBV), connective 
tissue diseases (CTDs) and lymphoproliferative disorders. Approximately 10% of 
patients have no identifiable cause and in this case it is referred to as “essential 
mixed cryoglobulinemia” [52]. Type III cryoglobulinemia (25-30% of cases) is 
characterized by polyclonal IgM with RF activity and polyclonal IgG and it’s seen 
in CTDs or secondary infection (mainly HCV). However, there are unusual 
cryoglobulins showing a micro-heterogeneous composition, whose 
immunochemical structure cannot be fitted into any of the categories described 
above. Using sensitive methods, such as immunoblotting or two dimensional 
polyacrylamide gel electrophoresis, some authors described MC formed by 
oligoclonal IgMs and traces of polyclonal immunoglobulins and their inclusion in 
the Brouet classification as type II-III variant has been proposed [53,54]. The IgM 
micro-heterogeneity, identified in about 10% of cases, has been considered as 
possible intermediate state in the transition from type III to type II MC; this 
serological condition and the transformation from polyclonal to oligoclonal and 
finally monoclonal IgM-RF fraction, reflects the continuous B cell clones expansion 
[54]. 
The process of cryoprecipitation is not entirely understood and probably differs 
between type I and II/III. In type I, the monoclonal component undergoes 
crystallization and aggregation, which is dependent on temperature and 
concentration [55]. Although the definition of cryoglobulins is precipitation at cold 
temperatures, this process can occur at room temperature at high cryoglobulin 
concentrations [46]: this fact probably explains why distal extremities (lower 
temperatures) and kidneys (increase in concentration as a result of ultrafiltration) 
are major sites of pathology. In type II/III cryoglobulinemia, cryoprecipitation takes 
place in the setting of immune complex formation between polyclonal IgG and IgM 
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with RF activity and complement fixation. Cryoprecipitation cannot be induced by 
the IgM or IgG components separately and requires specific antigen-avidity IgG 
molecules [56]: this aspect emphasizes the unique properties of cryoglobulins and 
explains the high incidence of HCV as a cause. Although the real mechanism of in 
vitro cryoprecipitation is rather obscure, non-specific Fc-Fc interactions might 
explain the self-aggregation of some Igs. Modifications of the primary structure of 
heavy and light chains are responsible, at least in part, for the different solubility of 
cryoglobulin and many studies on chemical analysis of cryoglobulins revealed a 
reduced concentration of sialic acid or a reduced amount of galactose in the Fc 
portion of the Ig. Furthermore, the solubility of proteins also depends on various 
factors such as concentration and temperature. Decreasing the temperature causes 
changes in the steric conformation of the molecules exposing non-polar residues 
resulting in solubility loss. Another factor is the pH of the solution, which may affect 
secondary and tertiary structures of immunoglobulins [57]. 
In the presence of cryoglobulins in serum, the diagnosis of cryoglobulinemia is 
based on typical clinical manifestations; false negative results may occur as a 
consequence of improper sample handling. Samples should be transferred and 
centrifuged at 37°C to avoid precipitation before serum extraction. In type I, 
precipitation at 1 to 4 °C usually occurs within hours; samples should be stored for 
7 days because precipitation can be delayed in the mixed types [58]. When 
cryoglobulins are detected, the measurement of the cryocrit, defined as the relative 
volume of the precipitate as a percentage of the total serum volume, should be 
reported. The correlation between the cryocrit and disease manifestation is poor 
[59,60], although higher cryocrit has been reported to increase the likelihood of 
symptomatic disease [52]; in a few studies the cryocrit was prognostic but overall, 
its use should be reserved for diagnosis because there is a poor correlation between 
the cryocrit and the response to treatment [58]. In normal human sera small 
amounts of cryoprecipitable immunoglobulins are frequently detected, reflecting 
specific molecular interactions between Ig molecules [61]. On the contrary, the 
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cryoprecipitation process occurring in cryoglobulinemia is caused by intrinsic 
characteristics of both monoclonal and polyclonal IgM components and can also be 
caused by interaction among single components of the cryoprecipitate.  
 
1.4 HCV-associated mixed cryoglobulinemia 
MC is the most frequent and well known extrahepatic manifestation developing 
during HCV infection; it is an autoimmune and non-malignant LPD characterized 
by the expansion of monoclonal IgM+CD27+ B cells producing a polyreactive natural 
antibody (Ab) endowed with RF activity. Upon binding of these monoclonal IgMs 
to the endogenous polyclonal IgGs, the resulting immune complexes 
(cryoglobulins) may precipitate and settle on the small vessels (predominantly 
capillaries, venules or arterioles) causing vascular inflammation within the skin, 
joints, peripheral nervous system and/or kidneys [62].  
The major clinical manifestations of MC syndrome include palpable purpura, renal 
disease, arthralgias or arthritis, nonspecific systemic symptoms including 
weakness, peripheral neuropathy and hypocomplementemia (with the fall in C4 
levels often being most prominent) [60,63,64]. The triad of purpura, arthralgia and 
weakness, named “Meltzer’s triad”, is well known but is seen in only one third of 
patients [65]. Purpura, which can be transient or persistent, is the most common 
manifestation: it’s seen in up to 90% of patients and is a key feature of the diagnosis 
[56]. Patients may present with various combinations of these features and different 
manifestations may predominate at different times in an individual patient. The 
cryoprecipitate also contains most of the viral antigens, their corresponding 
antibodies and HCV-RNA whose concentration is from 10 to 1000 fold greater than 
in the supernatant; this fact support the primary role of HCV infection in 
cryoglobulinemia [66]. Several other findings suggested a close association between 
HCV and MC: the presence of HCV-RNA sequence in serum, bone marrow cells 
and PBMCs [67], the presence of anti-HCV antibodies, HCV antigens and viral RNA 
in the damaged tissues [68]. It is not yet clear why HCV induces the production of 
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MC in some patients but not in others, indicating that other factors may affect the 
development of cryoglobulinemia.  
The production of IgM RF molecules is one of the most important events for the 
emergence of cryo-precipitable immune-complexes [69]. In normal conditions, RFs 
are molecules involved in the presentation of antigens to T cells within an 
immunocomplex. A postulated hypothesis for the pathogenesis of HCV-related MC 
is that HCV initially stimulates the production of IgM without RF activity. The 
persistent antigenic stimulation of complexes composed by polyclonal IgG/HCV 
and HCV/very low density lipoprotein may induce somatic mutations causing the 
acquisition of RF activity [57].  
MC is frequently associated with the production of autoantibodies [70] including 
antinuclear antibodies (ANA), SSA/Ro and SSB/La [71], anti-cardiolipin and anti-
neutrophil cytoplasmic antibodies (ANCA) [72]. The mechanism by which HCV 
induces non-organ-specific autoantibodies is unclear and may involve the 
enhancement of B-cell activation through the binding of the E2 envelope 
glycoprotein to the CD81 activatory co-receptor [73] and the activation of the innate 
Toll-like receptor (TLR) 7 by viral RNA [74].  
An alarming complication of MC is represented by its evolution to B-NHL. Notably, 
the presence of MC in HCV positive patients may increase the risk to develop NHL; 
indeed, an Italian multicenter study showed an over 35-fold increased risk to 
develop NHL for HCV positive patients with symptomatic MC compared with the 
general population [75] and consecutively, approximately 8-10% of patients with 
HCV-MC progress to overt NHL. Even after eradication, HCV-MC patients may 
remain at high risk to develop a B-NHL [76]. The B-NHL subtypes most frequently 
described as being associated with HCV are marginal zone lymphomas (MZL), in 
particular splenic marginal zone lymphomas (SMZL), lymphoplasmacytic 
lymphoma (LPL), and diffuse large B-cell lymphoma (DLBCL) [77].  
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1.5 VH1-69-expressing B cells in mixed cryoglobulinemia 
The monoclonal RF of approximately 80% of patients with HCV-associated MC 
express a cross-reactive idiotype, called WA [78], which is commonly but not 
exclusively associated with the VH1-69 heavy chain variable gene and with the VK3-
20 light chain variable gene [33,35]. It has been shown that VH1-69-encoded 
stereotyped idiotypes are frequently expressed by chronic lymphocytic leukemia 
(CLL) cells and by some other human lymphoid malignancies, suggesting that these 
tumors arise as a consequence of the antigenic pressure by common epitopes [79]. 
A useful marker for investigating, by flow cytometry, MC monoclonal B cells 
putatively expressing the WA idiotype is represented by the monoclonal antibody 
G6, directed to the VH1-69 protein product [33]; indeed, increased proportions of 
G6-positive B cells were found in 30% of patients with HCV-associated MC [80]. 
Studies of hybridomas and of cloned immunoglobulin genes derived from patients 
with HCV infection [81,82] suggested that, in addition to RF activity, the VH1-69-
encoded idiotype recognizes the E2 envelope glycoprotein of HCV. Interestingly, 
germline VH1-69 is also preferentially used by neutralizing antibodies against 
human influenza A virus [83] and HIV-1 [84], suggesting that the VH1-69 variable 
gene plays a key role in primordial antiviral defense by encoding natural antibodies 
reactive with broadly shared, conserved structural elements important for 
infectivity. In patients with HCV-associated MC, VH1-69-expressing B cells 
accumulate massively and, in some cases, replace the entire pool of circulating B 
cells. However, the absolute B cell numbers remain within normal limits and these 
patients have no signs of malignancy indicating that, although B cell homeostasis is 
subverted in MC, control mechanisms constrain the clonal expansion of VH1-69+ B 
cells, unless genetic changes take place [33]. The phenotype of the monoclonal VH1-
69-expressing B cells that accumulate in the blood of MC patients has been 
thoroughly investigated.  
By making use of the VH1-69-specific G6 and G8 antibodies, it was shown [33,85] 
that these cells are phenotypically heterogeneous and they can be distinguished into 
                                                                                                                                      Introduction 
	
 13 
two major populations [86,87]: one of them resembles typical IgM+IgD+CD27+CD21+ 
MZ B cells [88] and the other one is characterized by decreased expression of CD21, 
the CR2 complement receptor [89]. 
 
1.6 The complement receptor type II: CD21 
Complement receptor type II (CR2, CD21) is a 145-kDa glycosylated single 
polypeptide chain consisting of a long extracellular domain of 15-16 short consensus 
repeat sequences, a transmembrane region and a short cytoplasmic domain [90,91]; 
it is expressed on B cells [92], where its levels vary depending on the maturation 
stage of the cell, follicular dendridic cells, thymocytes and a subset of peripheral T 
cells [93,94]. Ligands of CD21 include the complement fragments C3d, C3dg and 
iC3b, that are covalently bound to the target antigens [95,96] and, in addition, it has 
been proposed to bind ligands such as the Epstein-Barr Virus (EBV) envelope 
glycoprotein gp350/220, the low affinity Fc-receptor for IgE (FceRII o CD23) and the 
cytokine interferon-alfa (IFN-a) [97].  
  
On B cell surface, CD21 forms a complex together with CD19 and CD81 (TAPA-1) 
[98,99], which functions as a co-receptor to the BCR. Upon simultaneous binding of 
complement-tagged antigens by CD21 and the BCR, the threshold for B cell 
activation is reduced [95,100]. In this scenario, CD21 acts as a bridge between the 
co-receptor complex and the BCR resulting in a co-ligation that induces the 
phosphorylation of the cytoplasmic tail of CD19 by BCR-associated tyrosine kinases 
and amplifies downstream signaling (Fig. 3) [95,101]. 
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Figure 3. The BCR and its co-receptor 
(Upper) The co-receptor complex, CD81, CD21 and CD19, and the membrane bound BCR together 
with its signal transduction molecules Ig𝛼 and Ig𝛽. (Lower) Upon simultaneous binding of 
complement-tagged antigens by CD21 and the BCR, the threshold required for B cell activation is 
reduced. Under these circumstances, CD21 acts as a bridge between the co-receptor complex and the 
BCR. The opsonizing complement fragments are C3d, C3dg or iC3b [112]. 
 
 
 
 
 
BCR
Ig! Ig"
CD19
CD21
CD81
Antigen recognition
C3d
Antigen
C3d
Antigen
C3d
Antigen
C3d
Antigen
B	cell activation
                                                                                                                                      Introduction 
	
 15 
CD21 plays an important role in the selection for high-affinity B cells as well as the 
development and maintenance of B cell memory [102]. Although the BCR co-
receptor function predominates, CD21 also mediates effects independent of the BCR 
including the induction of the transcription factor NF-kB, the production of 
interleukin-6 (IL-6) and the internalization of the antigen [95,103]. 
CD21 also exists in a soluble form, as the receptor can be shed from the plasma 
membrane by proteolytic cleavage in a short consensus repeat; indeed, it has been 
shown that CD21 is constantly shed from peripheral blood B lymphocytes and that 
its levels in blood are increased after cell activation. The amounts of soluble CD21 
in blood are also increased in diseases such as common variable immunodeficiency 
(CVID), B-CLL and malignancies associated with EBV [104], whereas the levels are 
decreased in autoimmune diseases [105]. Increased frequencies of a B cell subset 
expressing low levels of CD21 (CD21-/low B cells) have been described in several 
diseases characterized by a chronic immune stimulation: HCV-associated MC [85], 
HIV infection [106], malaria [107], CVID [108], rheumatoid arthritis (RA) [109], 
systemic lupus erythematosus (SLE) [110] and Sjögren’s syndrome [111].  
In all these different conditions CD21-/low B cells could appear not to be the same as 
they express different BCR isotypes, and these can be either mutated or unmutated; 
they also differ in their expression of CD27 so much so in some disorders they were 
selected based on being CD27+ or CD27-. Despite these differences there are several 
similarities between CD21-/low B cells expanded in the various diseases mentioned 
above, such as the expression of the inhibitory receptor Fc receptor like 4 (FcRL4 or 
FcRH4), increased levels of CD11c, and a pattern of activation and homing 
receptors, the latter indicating migration to inflammatory sites [112]. 
More than a decade ago a CD21-/low B cell subset was found in human tonsils and 
described as a novel CD27- memory B cell subset that expressed FcRL4 [113,114]; 
these cells were defined as memory B cells because most were switched and their 
BCRs contained somatic hypermutations (SHM). 
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Although CD21-/low B cells have been extensively studied in several diseases, data 
concerning the presence of these cells in peripheral blood from healthy individuals 
are relatively poor [112]. 
 
1.7 CD21low B cells in mixed cryoglobulinemia and in other disorders 
As previously reported, CD21low B cells of MC patients appear to be identical to 
those expanded in other immunological disorders with B cell hyperactivation, such 
as CVID, RA, and HIV infection. These cells, as well as those found in human 
tonsillar tissue, show signs of previous activation and proliferation, fail to 
proliferate in response to the stimulation of the BCR or of Toll-like receptor 9 
(TLR9), are unable to flux calcium upon BCR cross-linking and are highly prone to 
die by apoptosis [80,86,87]. The same behavior has been observed even in VH1-69+ 
IgM+IgD+CD27+CD21high MZ B cells, which therefore may be considered the 
precursors of their CD21low counterparts [85,89].  
A striking common trait is the expression of CD11c, the integrin 𝛼x chain, typically 
a marker of dendritic cells. The function of CD11c in CD21low B cells is unknown but, 
interestingly, this receptor is also expressed in some splenic marginal zone 
lymphoma (SMZL) and in hairy cell leukemia [115]. Another peculiar marker of 
CD21low B cells is the inhibitory receptor FcRL4, first described in a subset of human 
tonsillar B cells with low CD21 expression [113]. Other inhibitory receptors of 
CD21low B cells are CD22, Fc𝛾RIIB (CD32b), CD72, CD85j, CD85k, leukocyte-
associated Ig-like receptor-1 (LAIR-1) and sialic acid binding Ig-like lectin 6 (Siglec-
6) [108,109,116]. The contribution of these inhibitory receptors, and particularly of 
FcRL4 and Siglec-6, to the dysfunction of CD21low B cells is supported by the partial 
recovery of the proliferative capacity and of the effector function upon silencing of 
these genes with siRNA [117]. A further peculiarity of CD21low B cells expanded in 
MC and in the other disorders is represented by the profile of trafficking receptors: 
indeed, it is possible to identify an increased expression of CD11c and CXCR3, 
which allow homing to sites of inflammation, and a reduced expression of CCR7, 
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CD62L, CXCR4 and CXCR5, which are required for migration to lymph nodes or to 
germinal centers [89,108,116]. Human CD21low B cells resemble, under some aspects, 
an expanded population recently identified in aged mice. These cells, described as 
CD21low CD11c+ B cells and termed aged B cells (ABCs), are mostly autoreactive and 
develop more rapidly in female animals and in autoimmune-prone strains of mice 
[118,119]; interestingly, CD21low CD11c+ ABCs show the T-box expressed in T cells 
(T-bet) transcriptional factors which is important for the control of viral infection. 
Signaling through TLR7 is crucial for ABCs development; moreover, like human 
CD21low B cells, ABCs respond poorly to BCR or CD40 triggering but rather they 
robustly respond to the stimulation of TLR7 or TLR9 [120]. Recently, 
Tbet+CD21lowCD11c+ B cells similar to murine ABCs were found significantly  
expanded in patients with chronic Hepatitis C or cirrhosis and it has been 
demonstrated that clearance of HCV infection reduces their overall frequency 
indicating a dependence on infection [121]. 
Microarray profiling studies of CD21low B cells obtained from patients with MC 
[86,87] or with CVID [108,109] or from normal human tonsillar tissue [114] revealed 
common gene expression signatures. Among the differentially expressed 
transcription factors, the most strikingly up-regulated in CD21low B cells are sex 
determining region Y (SRY)-box 5 (SOX5), runt-related transcription factor 2 
(RUNX2), early growth response 2 (EGR2) and the zinc-finger homeobox 1B 
(ZFHX1B) that, interestingly, is deleted in HCV-associated high-grade diffuse large 
B cell lymphomas (DLBCL) [122]. Down-regulated genes include T cell 
leukemia/lymphoma1 (TCL1), which enhances B cell survival and is over-expressed 
in some B cell tumors, forkhead box 1 (FOXP1), a transcriptional repressor that is 
up-regulated in some DLBCL, and the IL-4 receptor. In CD21low B cells of MC 
patients it has been reported a striking up-regulation of Stra13, a basic helix-loop-
helix transcription factor that acts as a key negative regulator of activation and cell 
cycle progression in B cells [81]. Stra13 was also over-expressed by VH1-69+ 
monoclonal B cells with high expression of CD21, while it was scarcely expressed 
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by VH1-69+ B cells from patients with MC-associated SMZL [80]. Microarray studies 
[86] revealed that the CD21low B cells of MC patients display increased transcripts of 
genes that favor apoptosis, such as galectin-1 (LGALS1), pyrin and HIN domain 
family-1 (PYHIN1), death-associated protein kinase 2 (DAPK2), myeloid nuclear 
differentiation antigen (MNDA) and Fas (CD95). High expression of these genes 
correlated with increased spontaneous [87] and culture-induced [86] apoptosis of 
CD21low B cells.  
Although the differences in gene expression profiles of CD21low and CD21high VH1-
69+ B cells have not been adequately investigated, a clear-cut difference between 
these cell populations is represented by the lack of inhibitory receptors (e.g. FCRL4, 
CD22, CD72 and CD95) on CD21high B cells, whereas a common feature is the 
overexpression of Stra13 [80]. 
 
1.8 The nature of BCR-mediated anergy  
The ability of the adaptive immune system to provide protection against pathogens 
depends on a diverse repertoire of antigen receptors that allow recognition of a 
seemingly infinite range of foreign protein and carbohydrate antigens. Diversity is 
generated early in lymphocyte development by random rearrangement of 
immunoglobulin (Ig) genes; the random nature of this process leads inevitably to 
the generation of receptors that recognize self-antigens and that can be removed 
from the repertoire by a process of receptor editing [123] or clonal deletion [124]. 
However, despite these mechanisms of central tolerance silence B cells in the bone 
marrow, many self-reactive B cells escape to the periphery where they are silenced 
by anergy [125]. This last, defined as the failure to respond to BCR-mediated stimuli, 
is a component of normal B cell behavior [126]; it is a state of cellular lethargy 
resulting from the binding of the antigen by B cells (signal 1) in the absence of a 
significant CD4+ T cell help (signal 2).  
The concept of clonal anergy was first introduced in 1982 by Pike and Nossal, who 
observed that high doses of a monoclonal antibody with specificity for murine µ 
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chains (anti-Cµ), used as a “universal” B cell tolerogen because of its capacity to 
react with all emerging B lymphocytes regardless of specificity, prevented the 
development of normal numbers of B cells. By contrast, low concentrations of anti-
Cµ resulted in normal B-cells expansion. However, unlike B cells developed in the 
absence of any anti-Cµ, these cells showed impaired both proliferation and 
antibody formation, and abrogated functional capacity: in other terms they were 
functionally anergic [127].  
To explore the mechanism of anergy, it was necessary to develop transgenic mouse 
models in which this state of unresponsiveness can be induced in a controlled 
manner by creating a chronic interaction between antigen-specific B cells and 
antigen [126]. A favorite model, as well as the most widely studied, is represented 
by the hen egg lysozyme (HEL) double transgenic mouse, where persistent co-
expression of a high affinity HEL-specific BCR and soluble HEL results in an anergic 
status. As a consequence, these mice fail to mount adaptive responses following 
immunization with exogenous HEL, and they exhibit a reduced capacity to generate 
antibody-secreting cells in response to the Toll-like receptor (TLR) agonists CpG 
containing DNA and lipopolysaccharide (LPS). In a parallel arsonate (Ars)-specific 
model, the transgenic BCR has modest affinity for the Ars hapten, yet cross-reacts 
weakly with endogenous antigen (most likely single-stranded DNA) with a similar 
anergic outcome [128].  
It has been demonstrated that anergy is due to the continuous receptor occupancy 
by self-antigen, while antigen removal results in a rapid recovery of antigen 
receptor signaling [129]. Two key signaling features distinguish anergic cells from 
other types of B lymphocytes: reduced amplitude of phosphor-protein and Ca2+ 
responses to antigen receptor ligation and elevated constitutive protein 
phosphorylation in intact cells. These signaling properties have been found both in 
mice and humans [126,130].  
Although the pathways of positive BCR signaling in normal B cells which activate 
the signalosome and downstream pathways linked to proliferation, survival and 
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migration have been widely described [131], much less is known about signaling 
pathways operating in anergic cells. Chronic antigen signaling appears to lead to a 
shift in the balance between BCR-activation pathways and opposing inhibitory 
pathways but the means of achieving this are unclear [128]. As known, BCR has to 
be phosphorylated on the immunoreceptor tyrosine-based activatory motifs 
(ITAM) within Ig-α/Ig-β to initiate signal transduction. When the receptor is not 
engaged, ITAM are unphosphorylated and the BCR is off. Acute occupancy of 
receptors leads to bi-phosphorylation and consequent engagement of Syk tyrosine 
kinase and downstream effectors and adaptors (Fig. 4A). On the other hand, chronic 
BCR activation leads to ITAM mono-phosphorylation resulting in better activation 
of Lyn rather than Syk (containing dual SH2 domains, its activation requires two 
pY binding sites) and consequently in the stimulation of downstream inhibitory 
signaling pathways (Fig. 4B) [132]. This latter situation is typical of the anergic B 
cells. As part of feedback control, ITAM mono-phosphorylation results in the 
inhibition of signaling via phosphatases: SHIP1 activation plays a crucial role in 
anergy since it is constitutively phosphorylated in anergic cells. Other 
phosphatases, including SHP1 and PTEN, are also involved [133].  
What causes the partial activation of downstream signaling responses, such as 
increased ERK phosphorylation and activation of NFAT, without increases in other 
kinases and transcription factors associated with positive responses (including AKT 
and NF-kB) [134] is unknown. ERK activity may play a role in the inhibition of 
signaling responses via TLR9, which can also be suppressed in anergic cells [135]. 
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Figure 4. BCR signaling in naïve and anergic B cells 
Antigen triggers signaling that differs between naïve and chronically stimulated anergic cells. (A) 
In naïve B cells, antigen engagement triggers activation of Src-family kinases, including Lyn, which 
catalyzes the dual phosphorylation of immunoreceptor tyrosine-based activatory motifs within CD79 
and CD79B. This results in recruitment and activation of Syk and triggers activation of downstream 
effectors, including protein kinases (Akt, Btk) and adaptors (BLNK), as well as lipid metabolism via 
lipid kinases (PI3K) and lipases PLCγ2 leading to the production of lipid metabolites, PIP3, DAG 
and IP3. These pathways are naturally inhibited by Lyn-dependent activation of both protein (SHP1) 
and lipid (SHIP1) phosphatases. (B) In anergic cells, chronic BCR engagement favors mono-
phosphorylation of CD79A/B which results in weak Syk activation but efficient Lyn activation. 
Activation of phosphatases, especially SHIP1, further suppress Syk-dependent signaling by 
preventing accumulation of PIP3, and suppresses activation of BCRs and distinct receptors such as 
CXCR4. Anergic cells are often characterized by raised basal levels of iCa2+ and ERK 
phosphorylation [128].  
 
 
1.9 Functional exhaustion of VH1-69+ B cells in mixed cryoglobulinemia 
Many features of VH1-69+ CD21low B cells of MC patients, and particularly the 
transcriptional profile obtained from gene expression studies, highlighted a 
condition of anergy, defective proliferation and reduced survival.  
A decade ago, Moir and co-workers [116] defined the CD21low B cells of HIV-
infected patients “exhausted” rather than anergic by analogy with virus-specific 
immune cells that have lost function because of the chronic nature of the viral 
infection. Indeed, CD21low B cells differ from classical anergic B cells under some 
aspects and especially because, unlike in most models of B cell anergy [126], they 
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are at least in some cases poised to secrete in vitro high amounts of 
immunoglobulins [108,113].  
Several research groups have investigated whether, in HCV-associated MC, 
functional exhaustion is restricted to the VH1-69+ B cells with a CD21low phenotype 
or also concerns their CD21high counterpart: one of these groups showed that BCR-
induced phosphorylation of ERK kinase was impaired not only in the CD21low but 
also in the CD21high VH1-69+ monoclonal B cells of MC patients [80,89]; in contrast 
with these findings, other two groups have shown that BCR-induced Ca2+ flux was 
defective in CD21low but not in CD21high B cells of HCV+MC patients [86,87]. This 
discrepancy is most likely due to differences in the experimental design. Indeed, in 
the studies claiming that BCR signaling is defective only in CD21low B cells of MC 
patients, VH1-69+ B cells were not gated using the G6 antibody, since indirect 
staining with secondary anti-mouse Ig polyclonal antibody would have prevented 
experimental cross-linking of the BCR; therefore, the CD21high B cell populations 
examined were most likely contamined by normal polyclonal B cells. The other 
group [83] was also unable to gate the monoclonal B cells with the G6 antibody in 
BCR/ERK signaling experiments, but this problem was overcome by making use of 
negatively purified whole B cells from MC patients with a large predominance (70-
98% of B cells) of CD21high VH1-69+ B cells, thus providing a clear evidence that also 
these cells, and not only the CD21low subset, have a defect in BCR signaling. 
The CD21low but not the CD21high VH1-69+ B cells display also other features of anergy 
[86,87]. Comparing the capacity of FACS-sorted CD27+CD21low, CD27-CD21low, 
CD27+CD21high and CD27-CD21high populations of VH1-69+ B cells from MC patients 
to secrete IgM upon to co-stimulation with CD40 ligand (CD40L), IL2 and IL10, it 
was found that VH1-69+ CD21low B cells, irrespective of CD27 expression, secreted 
less IgM than their CD21high counterparts [86]. 
Interestingly, it was shown that CD21low but not CD21high B cells of MC patients 
failed to express activation markers and to proliferate in response to the stimulation 
with anti-IgM and CD40L, and that the VH1-69+ CD21low B cells responded normally 
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to the ligation of TLR9 with CpG [87]. However, unlike these findings, Visentini and 
co-workers [80,89] reported that the CD21low as well as the CD21high VH1-69+ B cells 
failed to proliferate in response to BCR or TLR9 ligation. The explanation of this 
difference is that in the first study the CD21low and the CD21high subsets seemingly 
included normally responsive polyclonal B cells, while in the second one [80,89] was 
exploited the staining with G6 antibody coupled to the CFSE dilution assay to 
unambiguously characterize the proliferative responses of VH1-69+ B cells to BCR or 
TLR9 stimulation. In addition, the claim that CD21low B cells of  
MC patients proliferate normally in response to TLR9 ligation [87] contrasts with 
previous data showing that the CD21low B cells from CVID or HIV-infected patients 
are poorly responsive to TLR9 stimulation [108,116]. Indeed, this statement [87] was 
not adequately supported by experimental data, since cells were stimulated with 
CpG in conjunction with anti-IgM and CD40L, a combination of stimuli known to 
override the unresponsiveness of CD21low B cells [80,116]. 
 
1.10 Evolution of antiviral therapy 
The therapeutic approach to MC has conventionally been based on the use of 
steroids and immunosuppressive drugs; the primary goal of antiviral therapy is the 
achievement of a sustained virological response at 12 weeks (SVR12), which is 
recognized as the measure of treatment success and defined as undetectable HCV 
RNA in the blood at the end of treatment and again 12 weeks following treatment 
end. IFN-based therapy was introduced in 1987, before the identification of HCV as 
the major etiologic factor of MC [136,137]. For several years, IFN-	𝛼 was the only 
agent available for the treatment of patients with chronic HCV infection; the 
addition of ribavirin (RBV), a guanosine analogue that produces broad-spectrum 
activity against several RNA and DNA viruses, to IFN-	𝛼 increased the SVR rate to 
about 50 % [138,139]. In 2000, pegylated (p) IFN-	𝛼, in which inert polyethylene 
glycol is attached to conventional IFN-	𝛼, was introduce into the clinical practice: 
this modified form of the drug showed a longer half-life, markedly improved SVR 
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rates and offered the further advantage of weekly rather than thrice a week 
administration [140]. There are two types of pIFN-	𝛼 which share over 95% amino 
acid sequence homology. As a result of their difference in size and structure, these 
two molecules have different in vivo and in vitro characteristics: while pIFN-	𝛼2a (40 
kDa) has a longer half-life, is mainly catabolized in the liver and has active 
breakdown products, pIFN-	𝛼2b (12 kDa) is a smaller molecule, has a shorter half-
life, and acts as a pro-drug depot by slowly releasing IFN.  
The antiviral combination of pIFN-𝛼 2a/2b plus ribavirin (RBV) was employed to 
obtain a SVR and, for many years, it has been considered the standard of care for 
the treatment of chronic HCV infection, capable of inducing SVR and clinical 
remission of vasculitis in about 78% of patients with MC [141,142].  
A multicenter, open-label study showed viral response rates ranging from 36% to 
64% according to viral genotype and a clinical response in 88% of the patients [143]. 
The association of rituximab (RTX), an anti-CD20 monoclonal antibody aimed at 
inducing an  
effective B cell depletion, resulted in further benefits both in patients refractory to 
antiviral therapy [144,145] and in those previously untreated [146]; however, the 
efficacy of therapy in terms of viral clearance remained unsatisfactory and was 
burdened with remarkable side effects.  
The use of first-generation protease inhibitors, such as boceprevir or telaprevir, 
associated with pIFN-	𝛼 + RBV in a triple-combination therapeutic regimen resulted 
in significantly higher response rates in patients with chronic HCV infection 
without and with MC; nevertheless, serious adverse events were recorded in almost 
50% of patients [147].  
The introduction of all-oral, direct-acting antiviral agents (DAAs) has dramatically 
changed the treatment of chronic HCV and consequently the prognosis of these 
patients. Thus far, four classes of DAAs have been discovered (Fig. 5): 
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               1) Protease inhibitors (asunaprevir, boceprevir, telaprevir, simeprevir, paritaprevir, 
                   grazoprevir, vaniprevir and voxilaprevir) 
 2) NS5A inhibitors (ledipasvir, daclatasvir, ombitasvir, elbasvir and velpatasvir)  
 3) Nucleotide polymerase inhibitors (sofosbuvir, dasabuvir) 
 4) Non-nucleotide polymerase inhibitors (deleobuvir, dasabuvir) 
 
 
 
 
 
Figure 5. HCV genome and potential drug discovery targets 
The HCV RNA genome serves as a template for viral replication and as a viral messenger RNA for 
viral production. It is translated into a polyprotein that is cleaved by proteases. All the HCV enzymes 
– NS2/3 and NS3-4A proteases, NS3 helicase and NS5B RNA dependent-RNA polymerase – are 
essential for HCV replication and are therefore potential drug discovery targets [148]. 
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Protease inhibitors are potent drugs that can inhibit the enzymatic activity of 
NS3/NS4A proteases while presenting several potential limitations: indeed, they are 
highly specific and as the amino sequence of the NS3 protease domain differs 
significantly between HCV genotypes, they exhibit varying activities across 
genotypes. For instance, telaprevir is less effective in treatment-naïve subjects 
infected with genotypes other than genotype 1. Furthermore, as HCV has a high 
mutation replication rate, with a lack of proofreading, resistance is an issue for this 
class of drugs [148]. NS5A inhibitors might inhibit replication complex formation at 
the endoplasmic reticulum and sequester NS5A in lipid droplets to prevent virus 
formation and release [149]; without affecting the stability and the dimerization of 
NS5A, NS5A inhibitors not only block HCV RNA synthesis at the stage of 
membranous biogenesis [150], but also impair viral assembly by inhibiting the 
delivery of  
HCV genomes to assembly sites [151]. In spite of their high potency, NS5A 
inhibitors slowly inhibit HCV RNA synthesis in comparison to HCV protease or 
polymerase inhibitors [152]. Nucleotide inhibitors bind to the catalytic site of NS5B 
and compete with incoming nucleoside triphosphates to interrupt the RNA 
synthesis. Non-nucleotide inhibitors bind to the allosteric binding pockets outside 
the NS5B catalytic site based on the non-competitive mechanism of action that 
inhibit the RNA synthesis [153]. 
All DAAs classes listed above are already available in Italy, except elbasvir, 
grazoprevir and velpatasvir, for which approval is pending. Because the antiviral 
efficacy of individual DAAs usually depends on HCV genotype, genotypic subtype 
and disease severity (e.g., cirrhosis) and many DAAs are prone to induce HCV 
resistance when used alone, combination regimens including two, three or even 
four DAAs, without pIFN-𝛼, have been developed and have become the new 
standard of care for HCV. These drugs have been shown to be capable of eradicating 
the infection in over 90% of patients with chronic HCV, with limited variations 
related to viral genotype [154]. An additional advantage of DAAs is the possibility 
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of avoiding IFN-related side effects. However, owing to the high costs of these 
drugs, it has been necessary to fix priority criteria among patients to be treated. Both 
the American and the European associations for the study of liver diseases, as well 
as the Italian Medicines Agency (AIFA), have established that extrahepatic 
manifestations of HCV infection, such as cryoglobulinemic vasculitis and 
lymphoproliferative disorders, should be recognized as priority indications for 
treatment with DAAs [155,156].  
So far, only a few papers have been published on the efficacy and safety of the use 
of DAAs in patients with MC. In particular, Gragnani et al. [157], in a prospective 
double-centre (Florence/Rome) study of a cohort of 44 consecutive patients with 
HCV-associated MC, 2 of whom had evolved into an indolent NHL with 
monoclonal B cell lymphocytosis, have shown that following guideline-tailored 
therapy with DAAs it is possible to achieve, in these patients, very high virological 
and clinical response rates: indeed, a striking reduction in the mean cryocrit value 
was revealed at SVR12, and an even greater reduction was observed for sustained 
virological response 24 weeks after therapy completion (SVR24); a partial vasculitis 
response and a roughly 50% reduction of cryocrit were detected in the two patients 
with lymphoma, and adverse events were rather frequent but usually mild [157]. 
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Chapter 2  
 
OBJECTIVE OF THE STUDY 
Anergy is one of the mechanisms that the immune system adopts to silence 
autoreactive B lymphocytes upon low-affinity recognition of self-antigens (Ag); in 
this condition, self-reactive B cells persist in the periphery yet remain unresponsive 
to immunogen. The molecular mechanisms of B cell anergy have been dissected in 
several transgenic mouse models [126]. A relevant issue was to understand whether 
the anergic status was induced after a transient exposure to a self-Ag and 
“remembered” or if it required continuous Ag receptor occupancy and signal 
transduction.   
Just over 10 years ago, Gauld and co-workers [129] explored this issue using an 
immunoglobulin-transgenic mouse model in which B cells were specific for the 
hapten arsonate (Ars) yet cross-reacted with a self-Ag that induced anergy in vivo. 
Their findings have clearly shown that continuous binding of Ag and subsequent 
receptor signaling are essential for the maintenance of the anergic status, since many 
features of B cell anergy can be rapidly reversed after dissociation of self-Ag using 
hapten competition, allowing these cells to recover Ag responsiveness.  
An elegant study conducted by Goodnow and co-workers has shown that in mice 
made tolerant by transgenic hen egg lysozyme (HEL) [135], ERK kinase is 
constitutively activated and provides a tolerogenic signal that inhibits TLR9-
induced plasma cell differentiation; interestingly, after disengagement of the BCR 
from the self-HEL the ERK phosphorylation was reduced. 
IgM+CD27+ B cells clonally expanded in patients with HCV-associated MC display 
peculiar phenotypic and functional features. In particular, these cells, chronically 
stimulated by HCV, display both features of anergy, induced by continual 
engagement of the BCR, such as high expression of the active phosphorylated form 
of the ERK kinase (pERK) and reduced lifespan, and of virus-specific exhaustion 
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such as a CD21low phenotype and defective response to the stimulation of the BCR 
and of TLR9. Identical CD21low B cells are also expanded in patients with CVID and 
in HIV-infected individuals; in these cells, the high constitutive expression of pERK, 
together with reduced calcium flux and propensity for apoptosis, makes them 
closely resembling murine B cells made anergic by continual BCR engagement by 
antigen.  
 
Usually MC regresses after eradication of HCV with IFN: indeed, in a study of 2012, 
Visentini and co-workers demonstrated that clinical signs of vasculitis regressed 
and the cryocrit values decreased significantly in all patients with sustained 
virological response (SVR) studied. In addition, they observed that HCV-RNA in 
serum became negative two to five months later the beginning of IFN-based therapy 
and both the absolute number and the percentage of VH1-69+ B cells declined in 
patients with SVR but not in virological non-responders [161].  
However, the immunomodulatory and anti-proliferative activities typical of IFN 
might contribute to the observed effects.  
In this work, I exploited the newly available DAAs, which rapidly suppress HCV 
viremia in HCV+MC patients and lack the immunomodulatory and anti-
proliferative properties typical of IFN, to find analogies with the mouse model and 
to untangle the effects of BCR disengagement in a human model of virus-driven 
anergy and exhaustion. 
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Chapter 3 
 
MATERIALS AND METHODS 
 
3.1 Mixed Cryoglobulinemia patients 
Twenty-four patients (8 males/16 females; median age 65 y, range 38-82 y) with 
HCV-associated MC vasculitis were treated with DAA combinations tailored 
according to current guidelines as previously described (Table 1) [157]. Thirteen 
patients were infected with HCV genotype (GT) 1, 8 with GT 2, 2 with GT 3 and 1 
with GT 4. Sixteen patients had chronic hepatitis and 8 cirrhosis. All patients had 
negative HCV viremia at the end of treatment (EOT) and sustained virologic 
response (SVR) through the follow-up; 3 patients were followed-up only for 12 
weeks (SVR12) and 20 for 24 weeks (SVR24) after completion of treatment. One 
patient was followed only up the EOT. Table 1 reports some of the patients’ 
demographic, clinical and treatment characteristics. 
 
 
Patient Age/gender HCV	
genotype
Liver
disease
DAA	therapy,
weeks	of	treatment
1 70/f 1b C SOF+SIM,	12
2 58/m 2 CH SOF+RBV,	12
3 77/f 1b CH SOF+LED,	12
4 69/m 1b CH SOF+LED, 12
5 57/m 4a C SOF+LED+RBV,	12
6 61/f 1b CH PAR/OMB/RTV+DAS,	12
7 58/f 1b CH SOF+LED+RBV,	12
8 38/f 3 C SOF+DCV,	24
9 58/f 1a CH SOF+LED+RBV, 12
10 63/f 1b CH SOF+LED,	12
11 78/f 2 CH SOF+DCV,	12
12 55/f 2 CH SOF+RBV, 12
13 52/m 1b CH PAR/OMB/RTV+DAS,	12
14 68/m 2 C SOF+RBV,	12
15 51/f 3 C SOF+RBV,	24
16 76/f 1b C SOF+LED+RBV,	12
17 75/f 2 C SOF+RBV, 12
18 72/m 2 CH SOF+RBV,	12
19 78/m 1b C SOF+LED,	12
20 59/m 1a CH SOF+LED,	12
21 82/f 1b CH SOF+LED,	12
22 77/f 2 CH SOF+RBV,	12
23 72/f 1a CH SOF+LED,	12
24 71/f 2 CH SOF+RBV,	12
Table 1. Demographic, clinical and 
treatment characteristics of HCV+ MC 
patients 
Abbreviations: C, cirrhosis; CH, chronic 
hepatitis; DC, decompensated cirrhosis; 
DAS, Dasabuvir; DCV, Daclatasvir; LED, 
Ledipasvir; PAR/OMB/RTV, Paritaprevir, 
Ombitasvir, Ritonavir; RBV, Ribavirin; 
SIM, Simeprevir; SOF, Sofosvubir. 
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3.2 Cells and immunophenotyping 
Peripheral blood mononuclear cells (PBMC) were obtained by density-gradient 
centrifugation. Immunophenotyping was done with combinations of fluorochrome-
labeled monoclonal antibodies (Becton- Dickinson Biosciences). The G6 monoclonal 
antibody, which recognizes an epitope of the VH1-69-encoded protein [158], was 
kindly provided by R. Jefferis (Birmingham, UK). Unlabeled G6 was counterstained 
with FITC- or PE-conjugated goat anti-mouse IgG (Becton-Dickinson Biosciences) 
using mouse IgG as control as previously described [33]. Flow cytometric analyses 
were done on a FACSCalibur instrument (Becton-Dickinson Biosciences) using the 
CellQuest (Becton-Dickinson Biosciences) and FlowJo (Tree Star, Ashland, OR) 
software. 
The gating strategy for enumerating CD21low B cells is depicted in Fig. 1. B cells are 
co-stained with anti-CD20 peridinin chlorophyll (PerCP), anti-CD21 phycoerythrin 
(PE) and additional fluochrome-labeled antbodies as requested. A consensus gate 
defining B cells with high CD21 expression (CD21high) was derived from the analysis 
of 11 healthy donors; setting the gate just below the cluster of CD21high B cells 
yielded percentages of B cells with low or no expression of CD21 (CD21low) of 5.8 ± 
2.5% (mean ± SD) in healthy donors and of 53 ± 23% in 24 patients with HCV+ MC. 
 
 
Figure 1. Gating strategy for enumerating CD21low B cells. CD20+ B cells from (A) one 
representative healthy donor and (B) one representative treatment-naïve patient with HCV+ MC are 
electronically gated and percentages of CD21low B cells are calculated on the basis of a predefined 
consensus gate positioned at the 102 fluorescence channel. 
 
Healthy donor HCV+ MC patient 
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3.3 PhosFlow assay for pERK 
The intracellular pERK content was measured by the BD Phos-Flow system as per 
manufacturer’s Protocol 1 (Becton-Dickinson Biosciences). PBMCs (1.5x106 cells) 
were split in two vials, re-suspended in 100 µL of RPMI 1640 containing 5% fetal 
bovine serum (complete medium), and equilibrated at 37°C for at least 20 min. An 
equal volume of prewarmed complete medium, either alone (unstimulated control) 
or containing 10 µg/mL of F(ab′)2 anti-human Ig (Jackson Immunoresearch 
Laboratories), was then added, and the cells were returned to 37◦C for 10 min. Cells 
were then fixed by the addition of 200 µL of prewarmed Phos-Flow Fix Buffer I for 
10 min at 37° C, washed twice in PhosFlow Perm/Wash Buffer I, split in two vials, 
and stained either with anti-pERK1/2-Alexa 488 or with mouse IgG-Alexa 488 as 
control. Samples were simultaneously stained with fluochrome-conjugated mAbs 
to CD20, CD27, IgM, or with other mAbs as requested by the experimental design 
(e.g. CD21 or G6). The pERK-specific MFI was calculated by subtracting the MFI 
values obtained with control mouse IgG from those obtained with anti-pERK 
antibody. A representative experiment is shown in Fig. 2. 
 
 
            3.4 ERK inhibition for apoptosis assays 
B cells from HCV+ MC patients were enriched (>97%) by means of negative 
immunomagnetic sorting. For pharmacologic inhibition of ERK, cells were pre-
incubated with 50 µmol/L U0126 (Calbiochem, San Diego, Calif) or dimethyl 
sulfoxide (vehicle) for 30 minutes at 37°C, before testing them for spontaneous 
apoptosis after 16 hours in vitro culture. After pre-treatment, the MEK/ERK 
A B 
Figure 2. Phos-Flow assay of pERK 
expression in unstimulated B cells. (A) 
healthy donor; (B) patient with HCV+ MC 
before DAA therapy. 
Open histograms denote staining with 
control antibody, and gray hystograms 
staining with anti-pERK. 
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inhibitor U0126 was added to the culture medium and all subsequent steps for 
apoptosis assays were done in the presence of 50µmol/L U0126 or dimethyl 
sulfoxide.  
 
3.5 Apoptosis assay 
A total of 106 PBMC in 1 mL of RPMI containing 10% fetal bovine serum were 
incubated at 37°C for 16 hours in 96-well U-bottom plates (2x105 cells/well), and 
then washed, resuspended in phosphate-buffered saline with 10% fetal calf serum, 
and stained with Annexin V–phycoerythrin (Molecular Probes, Life Technologies), 
7-amino- actinomycin (7AAD) (Sigma-Aldrich), anti-CD20 FITC and, in some 
experiments, G6 counterstained with PE-conjugated goat anti-mouse IgG. After 
electronic gating of CD20+ B cells, early apoptotic B cells were identified as annexin 
V+/7AAD-, and late apoptotic cells as annexin V+/7AAD+ cells; the values reported 
in the Results and Discussion section refer to total apoptotic B cells (early plus late). 
A representative experiment is shown in Fig. 3. 
 
 
 
 
 
Figure 3. Spontaneous in vitro apoptosis of B cells. After 16h in vitro incubation of PBMC in 
the absence of stimuli, cells were stained with anti-CD20, annexin V and 7-AAD. Electronically 
gated CD20+ B cells from (A) a healthy donor and (C) a patient with HCV+ MC were then analyzed 
for annexin V and 7-AAD staining. Early apoptotic B cells are identified as V+/7AAD- and late 
apoptotic B cells as V+/7AAD+; total (early plus late) apoptotic B cells are (B) ~4% in the healthy 
donor’s sample and (D) ~17% in the patient’s sample. 
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3.6 Cell proliferation assay 
Cell proliferation was measured by the carboxyfluorescein diacetate succinimidyl 
ester (CFSE) dilution assay [159]. PBMCs were labeled with CFSE (Invitrogen, Life 
Technologies) and cultured at 2 × 105 cells per well in 96-well U-bottom plates in the 
absence or presence of the TLR9 ligand CpG (2.5 µg/mL; Sigma Genosys). Cell 
proliferation was measured at day 5 of culture by flow cytometry. The number of 
cells that started dividing (precursor cohort) was calculated using the FlowJo 
software (Tree Star). Before flow cytometric analysis, cells were permeabilized 
(Permeabilizing-Solution 2; Becton-Dickinson Biosciences) and counterstained with 
antibodies to CD20, IgM and VH1-69 (G6 antibody), or with other antibodies 
according to the experimental design. Cell proliferation was measured in 
electronically gated whole CD20+ B cells or B cell subsets (e.g. VH1-69+ and VH1-69- 
B cells). Plasmablasts were identified as CD20low/neg cIgMhigh cells.  
 
3.7 Statistical analysis 
Data were analyzed by the Mann–Whitney U test for unpaired two groups, by 
paired or unpaired t test, or by Wilcoxon signed rank test for paired two groups. 
Data were analyzed with StatView 5.0.1 software (SAS Institute, Cary, NC). 
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Chapter 4 
 
RESULTS  
 
4.1 Typical features of clonal B cells expanded in HCV-associated mixed 
cryoglobulinemia 
Recent findings obtained in my laboratory have highlighted several typical features 
of clonal B cells expanded in HCV-associated MC [80]; the first step in my study 
was therefore to confirm the presence of these features even in patients enrolled.  
Monoclonal B cells of approximately 80% of patients with HCV+MC express a 
stereotyped idiotype which is commonly, but not exclusively, associated with the 
VH1-69 heavy chain variable gene [33,35]. By making use of the VH1-69-specific G6 
antibody, I could identify, among the twenty-four patients screened, six patients 
with high proportions of circulating VH1-69+ B cells; flow cytometric analysis of a 
representative patient is shown in the figure 1A (II) and is compared to a healthy 
donor (HD) in which VH1-69+ B cells were absent [Fig. 1B(II)].  
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Figure 1. VH1-69-expressing B cells in 
mixed cryoglobulinemia 
Peripheral blood lymphocytes (PBL) from 
one representative patient with HCV+MC 
(A) and one healthy donor (B) were co-
stained with antibodies to CD2  and VH1-
69 (or with mouse IgG as control). 
Dot plots show the electronic gating of 
VH1-69+ B cells (II), within total B cells 
(I), which are present in a high 
percentage in the HCV+MC patient (A II) 
and absent in the healthy donor (B II). 
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These monoclonal B cells, that accumulate massively in the blood of patients, 
display both features of anergy, induced by continual engagement of the B cell 
receptor (BCR), and of virus-specific exhaustion. In mouse models it has been 
shown that B cells constantly exposed, in vivo, to antigen, become anergic because 
continuous engagement of the BCR delivers tolerogenic signaling through ERK 
kinase phosphorylation [129]; to find a correspondence with the murine model, and 
to confirm previous observations [80], I investigated whether patients’ clonal B cells, 
which are chronically exposed to antigenic stimulation provided by HCV infection, 
display a similar pattern of constitutive and induced ERK phosphorylation.  
 
 
 
Figure 2. Constitutive and BCR-induced ERK phosphorylation  
Peripheral blood mononuclear cells (PBMCs) from patients with HCV-associated mixed 
cryoglobulinemia (HCV-MC) or from healthy donors (HDs), left unstimulated or stimulated with 
anti-Ig, were co-stained with antibodies to CD20, IgM, and with either anti-pERK or control 
antibody. CD20+ total B cells were analyzed for pERK expression. (A) Clonal B cells of HCV-MC 
patients display high constitutive pERK expression, compared to the expression levels observed in 
normal B cells of healthy donors (HD) (p=0.0003 using the Mann-Whitney test); both BCR-induced 
pERK expression (B) and pERK fold increase (C) were attenuated in HCV-MC patients compared 
to HDs (p=0.0003 and p=0.0001, respectively, using the Mann-Whitney test). Histograms denote 
mean values, expressed as Mean Fluorescence Intensity (MFI) and bars standard deviations.  
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In untreated patients, I noticed that clonal B cells expressed more basal pERK than 
normal B cells from the HDs (6.4±2.9% vs 3.2±1.2%, p=0.0003) [Fig. 2A], while BCR-
induced ERK phosphorylation [Fig. 2B], as well as the rate of increase in pERK after 
BCR ligation (fold increase) [Fig. 2C] were reduced (p=0.0003 and p=0.0001 
respectively). In particular, I observed that BCR cross-linking with anti-Ig induced 
a mean fivefold increase of pERK mean fluorescence intensity (MFI) in normal B 
cells and a mean threefold increase in HCV-MC B cells (4.73±1.43% vs 2.77±1.40%, 
p=0.0001) [Fig. 2C]. Uncoupling of constitutive and BCR-induced ERK activation 
was previously observed in CD21low B cells of HCV+ MC [82] and CVID patients 
[161]. 
 
Another typical feature of clonal B cells expanded in HCV+MC patients is the 
reduced lifespan [86,87]. To assess this, I performed apoptosis experiments after 16 
hours in vitro culture of B cells of untreated HCV+MC patients, or HDs, without 
stimuli. The results obtained showed that clonal B cells of enrolled patients have a 
higher proneness to spontaneous apoptosis compared to HDs (15±11.2% vs 
4.6±1.1%, p=0.0003) [Fig. 3A]. The figures 3B and 3C depict flow cytometric analyses 
of in vitro apoptosis without stimuli of B cells from a representative HD (3B) and a 
representative patient (3C). 
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Figure 3. Spontaneous in vitro apoptosis of B cells  
(A) Mean percentage of spontaneous in vitro apoptosis of B cells after 16h in vitro incubation of 
PBMCs without stimuli in patients with HCV+MC compared to healthy donors (bars denote 
standard deviations; statistical significance, indicated as p-value, was determined by the Mann-
Whitney test); (B-C) electronically gated CD20+ B cells from (B) one representative healthy donor 
and (C) one representative patient with HCV+MC were analyzed for annexin V and 7-AAD staining. 
Early apoptotic B cells are identified as annexin V+/7AAD- and late apoptotic B cells as annexin 
V+/7AAD+; total (eraly plus late) apoptotic B cells are (dot plot B) ~2% in the healthy donor’s sample 
and (dot plot C) ~21% in the patient’s sample. 
 
 
 
In addition to these anergy-like features [131,137], HCV+MC clonal B cells also 
displayed the features of exhausted B cells [83,89,90]: indeed, most of them showed 
the typical CD21low phenotype (8.1± 4.1% HDs vs 63.9± 14.9% HCV-MC, p<0.0001) 
[Fig. 4A] and failed to proliferate in response to BCR or TLR9 stimulation (CpG: 
37.9±7.8% HDs vs 18.0±17.1% HCV-MC, p=0.0150; CpG+Anti IgG-A-M: 72.4±7.1% 
HDs vs 27.5±20.3% HCV-MC, p=0.0001) [Fig. 4D]. 
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Figure 4. Phenotypic and functional features of clonal B cells of HCV-MC patients 
(A) Mean percentage of CD21low B cells in HCV+MC patients compared to healthy donors (p<0.0001 
using the Mann-Whitney test); (B-C) representative cytograms of one healthy donor (B), in which 
the proportion of CD21low B cells is 8,5%, and one patient (C) with 68% of CD21low B cells; (D) 
defective proliferative response in B cells of HCV+MC patients, compared to HDs, following TLR9 
and BCR stimulation (p=0.0150 and p=0.0001, respectively, using the Mann-Whitney test); 
histograms denote mean percentages and bars standard deviations. 
 
 
To assess whether, in patients’ clonal B cells, the high constitutive and attenuated 
BCR-induced pERK expression and the reduced lifespan were exclusive of CD21low 
cells or even concerned their CD21high counterparts, I evaluated these functional 
features in the two subsets. 
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Figure 5. pERK expression and spontaneous in vitro apoptosis in CD21low and CD21high B 
cells from HCV+MC patients  
(A) Both CD21low and CD21high B cells of HCV-MC patients display high constitutive and attenuated 
BCR-induced ERK phosphorylation, compared to HDs, although in both cases the expression levels 
of pERK are higher in the CD21low subset (p=0.0131 and p=0.0311 respectively, using the Mann-
Whitney test; histograms denote mean values, expressed as Mean Fluorescence Intensity, MFI, and 
bars standard deviations);(B) analysis of unstimulated (I) and stimulated (II) B cells of a 
representative patient for pERK expression in CD21low (gray-filled histograms) and CD21high (open 
black histograms) subsets (open blue histograms denote staining with control antibody);(C) CD21low 
B cells of HCV-MC patients are highly prone to die by spontaneous in vitro apoptosis compared to 
their CD21high counterparts, in which the mean percentage of apoptotic cells is ~1.1±0.9 (vs 
19.6±9.9%, p=0.0011 using the Mann-Whitney test; histograms denote mean percentages and bars 
standard deviations); (D) (I) electronically gated CD21low and CD21high B cells of a representative 
patient with HCV+MC were analyzed for annexin V and 7-AAD staining: early apoptotic B cells are 
identified as annexin V+/7AAD- and late apoptotic B cells as annexin V+/7AAD+; total (eraly plus 
late) apoptotic B cells are (II) ~22% in the CD21lowsubset and (III) ~1.2% in the CD21high subset.  
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First of all, I noticed that CD21high B cells of screened patients showed a lower level 
of constitutive ERK phosphorylation, compared to their CD21low counterparts 
(9.3±2% CD21low vs 5.8±1.8% CD21high, p=0.0131) [Fig. 5A, unstimulated], but still 
higher compared to that of HDs (3.2± 1.2%) [Fig. 2A]. BCR-induced ERK 
phosphorylation, as previously demonstrated [82,91], was impaired both in CD21low 
B cells (18.6±7.6%) and in CD21high B cells (14.5±5.5%), even though more 
accentuated in the latter (p=0.0311) [Fig. 5A, stimulated]. 
The analyses of spontaneous in vitro apoptosis revealed that the proneness to die is 
typical of CD21low B cells but not of their CD21high counterparts (19.6± 9.9% CD21low 
vs 1.1± 0.9% CD21high, p=0.0011) [Fig. 5C-D].  
 
4.2 Slow reduction of VH1-69+ and CD21low B cells after the withdrawal of chronic 
antigenic stimulation provided by HCV 
Four weeks after the beginning of therapy with DAA, when all patients were 
negative for HCV RNA, the proportions of CD21low B cells were unchanged (Pre-
therapy: 54.9±25% vs 4 weeks: 53.8±23%, p=NS) [Fig. 6A]. At the same time point, 
also the percentages of circulating VH1-69-expressing B cells remained unmodified 
(Pre-therapy: 51.7±36.4% vs 4 weeks:49.7±36%, p=NS) [Fig. 6B]. 
Monitoring clonal B cells phenotype over time, I observed that the proportions of 
CD21low B cells declined steadily up to SVR24 [Fig. 6C], although they remained on 
average higher than in healthy donors (5.8±2.5%). However, the proportions of VH1-
69+ B cells remained stable up to SVR24 in 3 out of 6 patients [Fig. 6D], suggesting 
that phenotypic changes occurred in clonal B cells after eradication of HCV as 
previously observed in HCV+ MC patients treated with IFN [161]. 
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Figure 6. Changes in clonal B cells phenotype 
No significant change in the mean percentage of CD21low (A) and VH1-69+ (B) B cells four weeks 
after the beginning of DAA therapy (the p value is not significant in both cases, using the Wilcoxon 
signed rank test for paired two groups); (C) slow but steady decline of CD21low B cells from baseline 
to SVR24; (D) changes in VH1-69+ B cell proportions over time; each line represents one patient 
followed from pre-therapy to SVR24. Histograms denote mean percentages and bars standard 
deviations; statistical significance, indicated as p-value, was determined by the Wilcoxon signed rank 
test for paired two groups. 
 
In the figure 7, which depicts flow cytometric analyses of VH1-69+ CD21low B cells in 
the 6 HCV+MC patients, is shown a comparison between the frequency of CD21low 
cells among VH1-69-expressing B cells before DAA therapy and the frequency of the 
same cells 24 weeks after the end of therapy (SVR24). Peripheral Blood 
Lymphocytes (PBL) were stained with fluorochrome-labeled antibodies to CD20, 
CD21 and VH1-69; CD20+ B cells were electronically gated and VH1-69+ cells were 
further gated for analysis of CD21 expression. Overall, data obtained in the 6 
patients studied indicate that the percentages of VH1-69+ B cells among total B cells 
decreased slightly from pre-therapy (51.2±35.7%) to SVR24 (41.8±39.1) (p=0.066), 
while the percentages of CD21low cells among VH1-69-expressing B cells decreased 
more markedly, from 84.8±9.9% in the pre-therapy to 41.5±12% at SVR24 (p=0.043), 
indicating a reversion of the CD21low phenotype. 
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Figure 7. Frequency of CD21low cells among VH1-69-expressing clonal B cells decreases 
after antiviral therapy 
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4.3 “Rapid” resetting of the signaling machinery after clearance of HCV viremia 
Another important observation made in the mouse model is that many features of 
anergic B cells, including high basal phosphorylation of ERK kinase, can be rapidly 
reversed after the dissociation of self-antigen from the BCR [129]. Similar to murine 
B cells made tolerant by constant BCR occupancy, clonal B cells expanded in 
HCV+MC might be rendered anergic by continual stimulation due to chronic HCV 
infection; however, already after the first weeks of DAA therapy there’s the 
clearance of HCV viremia, so that the chronic stimulus is missing. To further 
investigate the analogies with the mouse model, I analyzed ERK phosphorylation 
in some of the patients enrolled before and after the beginning of treatment. 
        
 
Figure 8. Early reduction of constitutive ERK phosphorylation in patients’ total B cells 
(A) Changes in constitutive pERK expression in clonal B cells of HCV+MC patients; (B) rate of 
increase in pERK (fold increase) after BCR ligation; (C) mean proportions of CD21low B cells from 
baseline to end of therapy (EOT). Histograms denote mean values, expressed as Mean Fluorescence 
Intensity (MFI) and bars standard deviations. Statistical significance, indicated as p-value, was 
determined by the Wilcoxon signed rank test for paired two groups  
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Four weeks after the beginning of DAA therapy, when all patients screened were 
negative for HCV viremia, constitutive ERK phosphorylation was significantly 
reduced compared to the pre-therapy levels (7.07±2.61 Pre-th vs 4.8±1.20 4w, 
p=0.0284) [Fig. 8A], although the rate of increase in pERK after BCR ligation (fold 
increase) increased only slightly (2.804±1.51 Pre-th vs 3.36±1.33 4w, p=0.0926) [Fig. 
8B]. At the end of therapy (EOT) no further variation was observed, neither in 
constitutive ERK phosphorylation nor in BCR-induced ERK phosphorylation [Fig. 
8 A-B].  
The possibility that early normalization of constitutive ERK activation was due to 
the replacement of clonal B cells by normal B cells contrasts with the observation 
that the proportions of CD21low B cells in these patients were unchanged at week 4 
of therapy (54.9±25% vs 53.8±23% pre-therapy, p=NS) [Fig. 8C]. 
 
To confirm the result obtained in total B cells of screened patients, I evaluated 
changes in pERK expression in the CD21low subset. Also in this case, four weeks after 
the beginning of DAA therapy there was a significant reduction of constitutive ERK 
phosphorylation both in CD21low (9.3±2.0% Pre-th vs 6.6±1.6 4w, p=0.0026) and in 
CD21high B cells (5.8±1.8% Pre-th vs 4.3±1.7% 4w, p=0.0277) [Fig. 9A]. At the end of 
treatment (EOT) no further significant reduction was observed in either of the two 
subsets [Fig. 9A]. BCR-induced ERK phosphorylation [Fig. 9B] was significantly 
increased at week four of therapy, compared to the pre-therapy levels, both in 
CD21low (18.6±7.6% Pre-th vs 22.6±7.7% 4w, p=0.0226) and in CD21high B cells 
(14.5±5.5% Pre-th vs 16.9±5.6% 4w, p=0.0185) [Fig. 9 B-C]. The relative increment, or 
fold increase, of pERK after BCR stimulation also significantly increased, from 
baseline to EOT, in both B cell subsets [Fig. 9C]. 
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Figure 9. Changes in pERK expression in the CD21low subset compared to their CD21high 
counterparts. Histograms denote mean values, expressed as Mean Fluorescence Intensity (MFI) 
and bars standard deviations. Statistical significance, indicated as p-value, was determined by paired 
t-test. 
 
4.4 Reduction of clonal B cells apoptosis after clearance of HCV viremia 
As I mentioned before, clonal B cells of untreated HCV+MC patients are highly 
prone to spontaneous in vitro apoptosis. Using a transgenic mouse model of B cell 
anergy, in which B cells were specific for the hapten arsonate (Ars) yet cross-reacted 
with a self-Ag that induced anergy in vivo, Gauld and co-workers [129] showed that 
the reduced lifespan of murine anergic B cells depended on chronic stimulation by 
self-antigen and that this effect could be reversed after the disengagement of the 
BCR. In order to evaluate whether even in clonal B cells of HCV+MC patients the 
reduction in the lifespan depends on chronic stimulation and can be reversed by the 
disengagement of the BCR, I analyzed B cell apoptosis in some of the patients 
enrolled before and after treatment with DAA. 
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Figure 10. Reduction of B cell apoptosis after clearance of HCV viremia 
(A) Reduction of spontaneous in vitro apoptosis of clonal B cells from HCV+MC patients after DAA 
therapy; each symbol represents a single patient studied once and bars denote the geometric means 
(statistical significance, indicated as p-value, was determined by the Wilcoxon signed rank test for 
paired to groups); (B) treatment with the MEK/ERK inhibitor U0126 failed to reduce spontaneous 
apoptosis of patients’ B cells (histograms denote the mean percentages resulting from experiments in 
4 different patients and bars denote standard deviations) 
 
 
Four weeks after the beginning of DAA therapy, when all patients screened were 
negative for HCV RNA, the percentages of B cell apoptosis were significantly 
reduced (Pre-therapy: 15±11.2% vs 4w: 10±13.2%, p=0.017) [Fig. 10A]. At the end of 
treatment (EOT) there is a further reduction, albeit lower than the previous one (Pre-
therapy: 15±11.2% vs EOT: 8±5.2%, p=0.0178) [Fig. 10A]. As well as for ERK 
signaling, even in this case the early normalization of spontaneous in vitro apoptosis 
cannot depend on the replacement of clonal B cells by normal B cells because the 
percentages of CD21low B cells, in these patients, were unchanged at week 4 of 
therapy (54.9±25% vs 53.8±23% pre-therapy) [Fig. 8C]. 
Although it is believed that reduced lifespan of murine anergic B cells is largely due 
to unfavorable competition for B-cell-activating factor (BAFF) [127], the rapid 
increase of lifespan after BCR disengagement suggests that chronic BCR signaling 
is sufficient to initiate apoptosis [132]. Thus, I investigated whether increased 
apoptosis of HCV+ MC B cells was related to ERK signaling; to this aim, I analyzed 
B cell apoptosis treating them with the U0126, a mitogen-activated protein kinase 
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(MEK) inhibitor that prevents MEK-dependent ERK phosphorylation. Treatment of 
MC B cells with U0126 failed to reduce spontaneous in vitro apoptosis, suggesting 
that ERK signaling is not directly involved in their pro-apoptotic pathway [Fig. 
10B].  
Even in this case, I confirmed the result obtained in total B cells evaluating 
spontaneous in vitro apoptosis in the CD21low subset. As indicated in the figure 11, 
the decrease in the proportions of apoptotic cells from pre-therapy to the end of 
treatment is confirmed also in CD21low B cells [Fig. 8]. 
 
 
 
Figure 11. Proneness to die by apoptosis is typical of CD21low B cells but not of their 
CD21high counterparts 
Reduction of spontaneous in vitro apoptosis in CD21low B cells, from baseline to end of therapy 
(EOT). Histograms denote mean percentages and bars standard deviations. Statistical significance, 
indicated as p-value, was obtained by the nonparametric Wilcoxon signed rank test for paired two 
groups. 
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4.5 Clonal B cell failure in recovering proliferative capacity after clearance of 
HCV viremia 
As previously reported by my research team, both CD21high (MZ-like) and CD21low 
VH1-69+ B cells of untreated HCV+ MC patients are functionally exhausted, since 
they fail to proliferate in response to the stimulation of TLR9 and BCR with their 
respective ligands [89]. After confirming this observation, already shown in the 
figure 4D of the paragraph 4.1, I investigated the possibility that VH1-69+ B cells 
could recover their proliferative capacity after removal of viral stimulus by DAA 
therapy. To this aim, as described in detail in Materials and Methods, CFSE labeled 
PBMCs were stained with the G6 antibody at the end of cultures. The strategy of 
analysis in a representative patient is illustrated in Figure 12. First of all, as 
previously shown in my laboratory [80], I observed that VH1-69+ B cells of untreated 
patients were unresponsive to CpG (Fig. 12A III) whereas autologous non-clonal 
VH1-69- B cells proliferated robustly upon TLR9 stimulation (Fig. 12B II). At SVR24, 
when the viral stimulus was no longer present due DAA treatment, the situation 
doesn’t change: indeed, the number of VH1-69+ B cells entering division (precursor 
cohort) was only 4% in the pre-therapy (Fig. 12A III) and just 8% twenty-four weeks 
after the end of therapy (SVR24) (Fig. 12B III).  
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Figure 12. The VH1-69+ clonal B cells of HCV+ MC patients fail to proliferate in response 
to TLR9 stimulation  
Strategy for the analysis of the proliferative responses of VH1-69+ and VH1-69- B cells before therapy 
(A) and at SVR24 (B) is shown. At the end of a 5-day culture in the presence of stimuli (CpG), CFSE 
labeled peripheral blood mononuclear cells (PBMCs) were permeabilized and stained with antibodies 
to CD20, IgM and VH1-69 (or with mouse IgG as control). VH1-69+ and VH1-69- B cells were 
analyzed for CFSE fluorescence (histograms). Percentages in the histograms denote the percent of 
divided cells (number of precursor B cells that have undergone at least one division). 
 
 
 
This observation was confirmed in three other patients studied before antiviral 
therapy and at SVR24. The table 1 summarizes data concerning the proliferative 
responses of VH1-69+ and VH1-69- B cells following stimulation with CpG (patient 
number corresponds to the Table 1 reported in Materials and Methods; findings in 
patient n. 7 are also reported in the figures 12 A-B).  
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Table 1. Proliferative responses to CpG stimulation 
The table summarizes data on the proliferative responses of VH1-69+ and VH1-69- B cells to 
stimulation with CpG in 4 patients (n. 3,7,15 and 22 in the table 1 in Materials and Methods) 
studied before antiviral therapy and at SVR24; findings in one of these patients (n.7) are also reported 
in the figure 12 of this paragraph. Results in 12 healthy donors, in which whole CD20+ B cells were 
gated for the analysis of proliferation, are also reported. Numbers in the Table denore the percentages 
of cells that started dividing (precursor cohort) after activation with CpG. 
 
 
The number of VH1-69+ cells entering division (precursor cohort) in the 4 patients 
analyzed was 2.4 ± 1.2 in the pre-therapy and 4.8 ± 2.1 at SVR24, whereas it was 35.2 
± 5.3 and 34 ± 7.3, respectively, in autologous VH1-69- cells. These findings indicate 
that, despite the reversion of the CD21low phenotype, as indicated by the decrease in 
the proportions of VH1-69+ CD21low cells from 84.8±9.9% in the pre-therapy to 
41.5±12% at SVR24 (p=0.043), long-lived clonal B cells failed to restore their capacity 
to proliferate in response to TLR9 stimulation. 
3 1.7 3.7 33 26
7 4 8 43 42
15 2.7 4.1 31 30
22 1.26 3.5 34 38
Mean ± SD 2.4 ± 1.2 4.8 ± 2.1 35.2 ± 5.3 34 ± 7.3
Patient n.
Pre-therapy Pre-therapySVR24 SVR24
VH1-69-positive VH1-69-negative
Healthy donors 37.9 ± 7.7
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Chapter 5 
 
DISCUSSION 
Mixed cryoglobulinemia (MC) is the most frequent and well known extrahepatic 
manifestation caused by chronic HCV infection and characterized by systemic 
vasculitis and lymphoproliferation. In this disorder HCV induces the non-
malignant monoclonal expansion of B cells producing a polyreactive natural 
antibody which is commonly encoded by the VH1-69 and VK3-20 genes and has both 
rheumatoid factor and anti-HCV activity [33,85]. The technical ability to identify 
isolate HCV-specific B cells through an anti-idiotype VH1-69-specific antibody (G6 
antibody) has made this condition an important model for studying humoral 
immune dysfunction during human chronic viral infection. 
Our group and others [85] have previously shown that clonal B cells of patients with 
HCV+MC display peculiar phenotypic and functional features: in particular, they 
commonly express low levels of CD21 (CD21low B cells), express a typical array of 
inhibitory and apoptosis-related genes and a distinctive pattern of homing 
receptors including CD11c, fail to flux calcium upon B cell receptor (BCR) triggering 
and to proliferate in response to the stimulation of BCR or of Toll-like receptor 9 
(TLR9), and are highly prone to die by apoptosis [80,86,87]. Identical CD21low B cells 
are also expanded in patients with common variable immunodeficiency (CVID) 
[160] and in HIV-infected individuals [106]. These CD21low B cells have been defined 
“exhausted”, rather than anergic, for their similarity with virus-specific exhausted 
T cells [106]; moreover, for some of their chatacteristics, human CD21low B cells recall 
the murine “aged B cells” (ABCs) increased in aged mice [118,119], which are 
CD21lowCD11c+ B cells expressing the T-box expressed in T cells (T-bet) 
transcriptional factor and are important for the control of viral infections [120].  
Just over 10 years ago, Gauld and co-workers [129], using a transgenic mouse model 
of B cell anergy, showed that constitutive ERK signaling and reduced lifespan are 
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reversed by the dissociation of self-antigen from the BCR, indicating the need for 
continual BCR occupancy for maintaining anergy. In 2014, Visentini et al. showed 
that CD21low B cells of HCV+MC and of CVID patients display high constitutive 
expression of the active phosphorylated form of the extracellular signal regulated 
kinase (pERK) [160]; this signature, together with reduced calcium flux and 
proneness to apoptosis, makes these cells closely resembling murine B cells made 
anergic by continual BCR engagement by antigen [135].  
Usually MC regresses after eradication of HCV with interferon (IFN), whose 
immunomodulatory and anti-proliferative activities might contribute to this effect. 
In this study, I exploited the newly available Direct Acting Antivirals (DAAs), 
which rapidly suppress HCV viremia in HCV+MC patients and lack the 
immunomodulatory and anti-proliferative properties of interferon, to evaluate the 
impact of eliminating chronic antigen exposure on B cell behavior, untangling the 
effects of BCR disengagement in a human model of virus-driven anergy and 
exhaustion. 
First of all, I evaluated and then confirmed that all the typical features of clonal B 
cells expanded in HCV+MC, previously reported by my group [85], were also 
present in patients enrolled in this study. In particular, I observed that clonal B cells 
of most patients with untreated HCV+MC had high basal levels of pERK, while both 
BCR-induced ERK phosphorylation and the rate of increase in pERK after BCR 
ligation (fold increase) were reduced. Uncoupling of constitutive and BCR-induced 
ERK activation has been observed not only in CD21low B cells, confirming previous 
observation in HCV+MC [84] and CVID [160] patients, but also in their CD21high 
counterparts; furthermore, I noticed that CD21high B cells of HCV+MC patients 
showed a lower level of constitutive and BCR-induced ERK phosphorylation, but 
still higher compared to healthy donors. Patients’ B also had increased apoptosis 
upon in vitro culture without stimuli and this proneness to die seems to be typical 
of CD21low B cells but not of their CD21high counterparts. 
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In addition to these anergy-like features [129,135], clonal B cells also displayed the 
features of exhausted B cells [80,86,87] as they were mostly 
CD21lowIgM+CD27+CD11c+FCRL4+ and failed to proliferate in response to BCR or 
TLR9 stimulation.  
Four weeks after the beginning of DAA therapy, when all patients were negative 
for HCV RNA, constitutive ERK phosphorylation was significantly reduced 
compared to the pre-therapy levels, although BCR-induced ERK phosphorylation 
increased only slightly; this observation, obtained in patients’ total B cells, was 
confirmed both in CD21low and CD21high subsets. At this time point, spontaneous in 
vitro apoptosis was also significantly reduced. The possibility that early 
normalization of constitutive ERK activation and apoptosis was due to the 
replacement of clonal B cells by normal B cells contrasts with the fact that the 
proportions of CD21low B cells in these patients were unchanged at week 4 of 
therapy. 
These results support the idea that, as in the case of antigen-induced reversible B 
cell anergy in mice [129], reduction in the lifespan of B cells of HCV+MC patients 
depended on chronic stimulation and could be reversed by disengagement of the 
BCR. Although it is believed that reduced lifespan of murine anergic B cells is 
largely due to the unfavorable competition for B cell-activating factor (BAFF) [126], 
the rapid increase of lifespan observed after BCR disengagement suggests that 
chronic BCR signaling is sufficient to initiate apoptosis [129]. Thus, I investigated 
whether reduced lifespan of MC B cells was related to ERK signaling; treating MC 
B cells with the MEK/ERK inhibitor U0126 failed to reduce spontaneous in vitro 
apoptosis, suggesting that ERK signaling is not directly involved in their pro-
apoptotic pathway.  
Monitoring clonal B cells phenotype over time, I observed that the proportions of 
CD21low B cells declined steadily up from baseline to SVR24, thus indicating a 
reversion of the CD21low phenotype, although they remained on average higher than 
in healthy donors. However, the proportions of VH1-69-expressing B cells remained 
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stable up to SVR24 in 3 out of 6 patients, suggesting that phenotypic changes 
occurred in clonal B cells after eradication of HCV, as previously observed in 
HCV+MC patients treated with IFN [164]. Despite phenotypic changes, I observed 
that long-lived clonal B cells failed to restore their capacity to proliferate in response 
to TLR9 stimulation. This indicated that HCV-driven B cell exhaustion makes use 
of durable reprogramming mechanisms irrespective of the CD21low phenotype, as 
suggested by previous studies [89,161]. 
Recently, T-bet+ CD21lowCD11c+ B cells similar to murine ABCs were found 
increased in patients with chronic hepatitis C or cirrhosis without MC and, 
importantly, eradication of HCV with DAAs led to their decrease indicating a 
dependence on infection [121]. Although I didn’t investigate and cannot exclude T-
bet expression in clonal B cells of MC patients, their CD27+IgD+IgM+ B cells [33,85] 
are phenotypically distinct from the T-bet+ B cells of HIV-infected patients without 
MC, which are mostly CD27-IgD-IgM-IgG+ class-switched cells [121]. Interestingly 
in this regard, while the T-bet+ CD27-IgG+ B cells of HCV-infected patients decrease 
after antiviral therapy, the few T-bet+IgD+IgM+ B cells appear to increase [121]. No 
data to date specifically link the anergy properties observed in cryoglobulin-
producing B cells and T-bet, but the phenotypic similarities mentioned above 
(CD21lowCD11c+) suggest a possible relationship that should be explored; the rapid 
upregulation of T-bet observed in convalescent CD21low B cells upon re-exposure to 
autologous HCV strains ex vivo [121], suggesting a link between BCR ligation, T-
bet and the CD21low exhaustion phenotype.  
In summary, I show that the rapid clearance of HCV viremia with DAAs, which 
unlike interferon do not act as immunological modulators, offers a unique model 
for untangling the interplay of virus-driven anergy and exhaustion in human B 
lymphocytes. Clonal B cells of HCV+MC patients display both signatures of anergy, 
induced by continual BCR occupancy, and of exhaustion driven by chronic viral 
infection; anergy features (pERK overexpression and accelerated apoptosis) rapidly 
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revert after disengagement from HCV, while phenotypic and functional features of 
exhaustion persist for several months.  
 
Much of the results showed in this thesis have been recently published on Blood 
journal (Del Padre et al., July 2017) [162] and the paper was also featured in “This 
Week in Blood”, a weekly snapshot of the hottest studies from each week’s issue of 
Blood. In this comment, the author, David E. Kaplan (University of Pennsylvania), 
attributes a clinical relevance to these data, asserting that the persistence of VH1-69+ 
B cells after clearance of HCV viremia clearly explains the persistence of 
symptomatic cryoglobulinemic vasculitis observed in some HCV-cured patients 
[163].  
In Kaplan opinion, the fact that B cell exhaustion phenotype is durably programmed 
into antigen-specific B cells suggests that B cell exhaustion might rapidly redevelop 
in the setting of reinfection, potentially contributing to the lack of protective 
immunity observed in many resolved chronic infections.  
In the conclusion of the comment, the author claims that this study creates the 
context for further exploration of the mechanisms associated with induction of B 
cell exhaustion in vivo. Once the regulation of B cell anergy in chronic infection is 
better understood, therapeutic manipulation could significantly affect the outcomes 
not only of chronic hepatitis C, but also of other chronic viral and parasitic infections 
[164]. 
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